Inadequate prescription-drug coverage for medicare enrollees - A call to action

New England Journal of Medicine

Volumn 340, Issue 9, 1999, Pages 722-728

  Soumerai, Stephen B ^a   Ross Degnan, Dennis ^a  

^a HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DISTRIBUTION; HEALTH MAINTENANCE ORGANIZATION; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0033522150     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199903043400909     Document Type: Review

References (40)

1. Rice T, Desmond K, Gabel J. Medicare Catastrophic Coverage Act: a post-mortem. Health Aff (Millwood) 1990;9(3):75-87.
2. Yankelovich D. The debate that wasn't: the public and the Clinton plan. Health Aff (Millwood) 1995;14(1):7-23.
3. Reinhardt UE. Turning our gaze from bread and circus games. Health Aff (Millwood) 1995;14(1):33-6.
4. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54.
5. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994;331:650-5.
6. Health Care Financing Administration, Office of Strategic Planning. A profile of Medicare: chart book. Rockville, Md.: Department of Health and Human Services, 1998.
7. Laschober MA, Olin GL. Health and health care of the Medicare population: data from the 1992 Medicare Beneficiary Survey. Rockville, Md.: Westat, November 1996.
8. Levit K, Cowan C, Braden B, Stiller J, Sensenig A, Lazenby H. National health expenditures in 1997: more slow growth. Health Aff (Millwood) 1998;17(6):99-110.
9. Davis M, Poisal J, Chulis G, Zaraboso C, Cooper B. Prescription drug coverage, utilization, and spending among Medicare beneficiaries. Health Aff (Millwood) 1999;18(1):231-43.
10. Baugher E, Lamison-White L. Poverty in the United States: 1995. Current population reports. Series P60-194. Washington, D.C.: Bureau of the Census, 1996:15.
11. Gross D, Caplan C, Gibson MJ. Estimates of financial burden of prescription drugs on beneficiaries in Medicare fee-for service. Washington, D.C.: American Association of Retired Persons, September 1998.
12. Gross DJ, Alecxih L, Gibson MJ, Corea J, Caplan C, Brangan N. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries. Health Serv Res (in press).
13. Soumerai SB, Ross-Degnan D, Fortess E, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Q 1993;71(2):217-52.
14. Pharmaceutical benefits under state medical assistance programs. Reston, Va.: National Pharmaceutical Council, November 1997.
15. University of Washington, Department of Pharmacy. Medicare managed care: opportunities and concerns for pharmaceutical benefits. Pharmaceutical Outcomes Research & Policy Program Report 1998;4(1):1-4.
16. Medex Gold enrollment halt sought. Boston Globe. November 10, 1998:D1.
17. Current knowledge of third party outpatient drug coverage for Medicare beneficiaries. Fairfax, Va.: Lewin Group, November 9, 1998.
18. National health expenditures, 1996. Health Care Financ Rev 1996; 19(1):171-3.
19. Lurie N, Ward NB, Shapiro MF, Brook RH. Termination from MediCal - does it affect health? N Engl J Med 1984;311:480-4.
20. The uncovered: drug costs can leave elderly a grim choice: pills or other needs. Wall Street Journal. November 17, 1998:1.
21. Fact sheet: 1999 Social Security changes. Baltimore: Social Security Administration, November 1998.
22. Testimony of Eva Berry, Joint Committee on Health and Human Resources, Legislature of the State of Maine. LD# 2218, an act to implement the recommendations of the Task Force on Improving Access to Prescription Drugs for the Elderly, Augusta, Me., March 9, 1998.
23. Limits loom for seniors' drug benefits. Boston Globe. November 17, 1998:A1.
24. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects of therapy, cost, and equity. N Engl J Med 1987;317:550-6.
25. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients: effects on cost, therapy, and out-of-pocket expenditures. Med Care 1996;34:686-701.
26. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991;325:1072-7.
27. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-15.
28. Gerdtham U-G, Hertzman P, Jonsson B, Boman G. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991. Med Care 1996;34:1188-98.
29. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887-91.
30. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802. [Erratum, Circulation 1996;94: 849.]
31. Fineberg HJ, Pearlman LA. Surgical treatment of peptic ulcer in the United States: trends before and after the introduction of cimetidine. Lancet 1981;1:1305-7.
32. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-7.
33. Health Care Financing Administration, Office of Strategic Planning. A profile of Medicare: chart book. Rockville, Md.: Department of Health and Human Services, 1998:10.
34. Pharmaceutical benefits under state Medicaid assistance programs. Reston, Va.: National Pharmaceutical Council, 1997:2-33-2-36.
35. Sheils JF, Fishman A. Comprehensive Medicare reform: defined benefit vs. defined contribution. Fairfax, Va.: Lewin Group, 1998.
36. Drug companies slam Medicare-Discount Bill. Wall Street Journal. December 18, 1998:B1.
37. Drug prices: effects of opening federal supply schedule for pharmaceuticals are uncertain. Washington, D.C.: General Accounting Office, 1997. (GAO/HEHS-97-60.)
38. Medicaid: changes in best price for outpatient drugs purchased by HMOs and hospitals. Washington, D.C.: General Accounting Office, 1994. (GAO/HEHS-94-194FS.)
39. Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA 1990;263:549-56.
40. Hard to swallow - America's soaring drug costs. Wall Street Journal. November 16, 1998:A1.